Key result
Fus knockdown inhibits AngII-induced cardiac fibroblast proliferation and collagen synthesis via Pax3 and TGF-β1/Smad signaling.
Why the study?
The AngII/TGF-β1 axis regulates atrial fibrosis contributing to AF, and FUS was recently found to regulate cardiac diseases, prompting investigation into whether FUS regulates AngII-induced fibrosis.
Does Fus knockdown prevent AngII-induced atrial fibrosis via the Pax3/TGF-β1/Smad pathway in cardiac fibroblasts?
Does Fus knockdown prevent AngII-induced atrial fibrosis via the Pax3/TGF-β1/Smad pathway in cardiac fibroblasts?
p-value: p=<0.001
The Fus/Pax3 axis represents a novel regulatory pathway in atrial fibrosis and may serve as a potential therapeutic target in atrial fibrillation.
Fus/Pax3 axis may modulate fibroblast activity in models; leaves open therapeutic targeting in atrial fibrillation.
The Angiotensin II/transforming growth factor-β1 (AngII/TGF-β1) signal axis is an important regulatory pathway for atrial fibrosis, which can contribute to atrial fibrillation (AF). Fused in sarcoma (FUS) was recently found to regulate cardiac diseases. This study aimed to investigate whether FUS could regulate AngII induced fibrosis and uncover the possible mechanisms. The expression of FUS in AF patients and AngII-induced cardiac fibroblasts was measured by RT-qPCR and western blot assays. Fus was silenced in cells using short hairpin RNA (shRNA), then cell proliferation, migration, collagen synthesis and TGF-β1/Smad signaling were detected by CCK-8, wound healing and western blot assays, respectively. The possible target for Fus was predicted by searching Starbase database and verified by RNA-binding protein immunoprecipitation (RIP) and RNA pull down. Cells were overexpressed with Pax3 in the presence of Fus silence and AngII stimulation, then the above cellular processes were further evaluated. Results showed that FUS was upregulated in AF patients and AngII-induced cardiac fibroblasts. Fus knockdown inhibited AngII-enhanced cell proliferation, migration, collagen synthesis and TGF-β1/Smad signaling activation. Furthermore, Fus functions as an RNA-binding protein to bind to Pax3 mRNA and positively regulate its expression. Further studies demonstrated that Pax3 overexpression canceled the above effects of Fus knockdown on cell proliferation, migration, collagen synthesis, and TGF-β1/Smad signaling activation in AngII-induced cells. In conclusion, Fus could target Pax3 to increase the pro-fibrotic effect of AngII in cardiac fibroblasts via activating TGF-β1/Smad signaling. Knockdown of Fus/Pax3 axis may provide a potential therapy for relieving AF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied Atrial fibrillation (n=60). Fus knockdown vs. Negative control was evaluated on Fus expression and profibrogenic cellular processes (proliferation, migration, collagen synthesis) (p=<0.001). Fus knockdown inhibited AngII-enhanced cardiac fibroblast proliferation, migration, and collagen synthesis by targeting Pax3 and regulating the TGF-β1/Smad pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: